LH

Labcorp Holdings Inc.

HealthcareDiagnostics & ResearchNASDAQ

$260.06

+$4.38 (1.69%)today

Conviction

7/ 10

Fair Value$309.47

Upside+19.00%

Signal13.3

Market Cap$22.0B

52W Range$209.38–$293.72

Next EarningsApr 30

Conviction History

Conviction Changes

Mar 18, 2026, 1:10 PM6→7conviction-rescore

Premium Content

Upgrade to premium to see the full reasoning behind each conviction change.

Price History

FAIR VALUE ANALYSISMonte Carlo · 5,000 runs · 99% valid

Fair Value$354.95

Current Price$263.00

Upside / Down+35.0%

P(Undervalued)84.7%

P(20%+ Up)66.6%

P(15%+ Down)6.3%

Fair Value Distribution — percentile bands

84.7% of simulations place fair value above current price

WHAT IS PRICED IN

Revenue-Based Reverse DCF

-0.4%/yr

±5.1% · revenue growth to justify current price

FCF-Based Reverse DCF

11.3%/yr

±3.0% · FCF growth to justify current price

THE GAP

Market pricing margin compression or rising capex

Premium Content

Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.

Bull Case

Labcorp lab testing volumes recovering; genomics/oncology testing growth; Medicare rate stabilization.

Bear Case

Reimbursement pressure from CMS; volume normalization post-COVID; revenue cycle complexity.

Updated Apr 7

Research Feed

sec_10kMar 3

Conviction: unchanged

LH FY2025: Strong margin expansion + strategic positioning in specialty diagnostics & CDx

FY2025 strong results: 7.2% revenue growth, 4.4% organic, both segments expanding margins. Margin expansion driven by operational leverage and mix improvement (specialty/CDx growth). Strategic positio...